Elevated serum MIC‐1 levels have previously been shown to be a potential surrogate PD biomarker of MDM2 inhibitor activity in RG7112 and idasanutlin clinical trials.25, 26, 27 Plasma and tumour samples were analysed using a human MIC‐1 ELISA assay, therefore any detected MIC‐1 is tumour specific (Fig. 2d, e). This evidence concerns the gene MDM2 and neoplasm.